Hospital
Natchitoches Parish Hospital Service District
Natchitoches Parish Hospital Service District was paid $21.40M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoNATCHITOCHES PARISH HOSPITAL SERVICE DISTRICT
NATCHITOCHES, LA 71457
NATCHITOCHES, LA 71457
33aNPI1689676835assigned 06/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.40M
24GClaims614,750
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#21 of 96
Median peer was paid$5.17M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,507 | $2.14M | |
| 2019 | 64,462 | $1.75M | |
| 2020 | 50,284 | $1.64M | |
| 2021 | 94,409 | $3.29M | |
| 2022 | 133,428 | $4.69M | |
| 2023 | 125,056 | $4.67M | |
| 2024incomplete | 83,604 | $3.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 49,039 | 41,749 | $5.95M |
| G0378 | Hospital observation service, per hour | 6.7% | 5,502 | 3,079 | $1.44M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5.7% | 4,220 | 3,329 | $1.22M |
| G0379 | Direct admission of patient for hospital observation care | 5.2% | 2,746 | 2,154 | $1.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.5% | 6,394 | 5,609 | $954K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 12,219 | 9,625 | $827K |
| A0425 | Ground mileage, per statute mile | 3.4% | 14,202 | 10,790 | $734K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 2.6% | 7,876 | 6,288 | $546K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.4% | 16,374 | 12,915 | $517K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 11,056 | 8,926 | $500K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 9,296 | 6,969 | $428K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 17,566 | 14,982 | $417K |
203 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 10,629 | $404K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 1,940 | $386K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 1,720 | $379K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 4,995 | $345K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 973 | $335K |
| 59025 | Fetal non-stress test | 1.1% | 2,831 | $238K |
| 80050 | General health panel | 1.1% | 5,869 | $225K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 6,494 | $218K |
| 80053 | Comprehensive metabolic panel | <1% | 29,502 | $203K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,756 | $203K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,443 | $200K |
| 93017 | <1% | 1,455 | $188K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,292 | $153K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 438 | $150K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 1,648 | $125K |
| 36415 | Collection of venous blood by venipuncture | <1% | 70,815 | $122K |
| 99285 | Emergency room visit (most serious) | <1% | 858 | $114K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,499 | $109K |
| 76801 | <1% | 761 | $106K | |
| 97597 | <1% | 1,957 | $103K | |
| 20610 | <1% | 802 | $89K | |
| 81025 | <1% | 12,819 | $89K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,302 | $84K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 671 | $82K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,907 | $81K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,701 | $70K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,735 | $63K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,312 | $61K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,280 | $60K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 94 | $58K |
| 87390 | <1% | 3,123 | $53K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 315 | $51K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,405 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,909 | $50K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 594 | $50K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,885 | $49K |
| 73562 | <1% | 748 | $45K | |
| 84439 | <1% | 7,214 | $45K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 558 | $44K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 212 | $42K |
| 83880 | <1% | 2,319 | $42K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,650 | $41K |
| 81003 | <1% | 30,981 | $39K | |
| 94726 | <1% | 370 | $37K | |
| 80061 | Lipid panel | <1% | 3,271 | $36K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 387 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,105 | $34K |
| 85730 | <1% | 8,881 | $34K | |
| 83970 | <1% | 1,372 | $33K | |
| 81001 | <1% | 17,315 | $31K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 381 | $31K |
| 86703 | <1% | 3,124 | $30K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,628 | $30K |
| 95117 | <1% | 2,627 | $28K | |
| 84484 | <1% | 4,653 | $28K | |
| 85610 | <1% | 9,461 | $26K | |
| 84702 | <1% | 2,437 | $26K | |
| 76830 | Ultrasound, transvaginal | <1% | 185 | $26K |
| 84144 | <1% | 1,693 | $25K | |
| 83690 | <1% | 4,864 | $24K | |
| 94729 | <1% | 382 | $23K | |
| 86803 | <1% | 1,870 | $18K | |
| 86885 | <1% | 3,031 | $18K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,052 | $18K |
| 82553 | <1% | 2,898 | $17K | |
| 87340 | <1% | 2,252 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,432 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,807 | $15K |
| 87070 | <1% | 2,401 | $15K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 90 | $15K |
| 86762 | <1% | 1,577 | $14K | |
| 86592 | <1% | 3,869 | $12K | |
| 82150 | <1% | 2,702 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,117 | $12K |
| 87088 | <1% | 2,089 | $12K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 584 | $12K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 214 | $11K |
| 73564 | <1% | 150 | $11K | |
| 83020 | <1% | 1,178 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,125 | $11K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 656 | $11K |
| 82550 | <1% | 2,894 | $11K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 31 | $9K |
| 94010 | <1% | 166 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 419 | $9K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 206 | $8K |
| 83735 | <1% | 2,364 | $8K | |
| 73630 | <1% | 205 | $8K | |
| 73560 | <1% | 128 | $8K | |
| 80069 | <1% | 1,478 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 376 | $7K |
| 74018 | <1% | 128 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 101 | $6K |
| 96376 | <1% | 122 | $6K | |
| 73130 | <1% | 109 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 374 | $6K |
| 73502 | <1% | 102 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 33 | $6K |
| 80076 | <1% | 1,165 | $5K | |
| 74240 | <1% | 59 | $5K | |
| 81000 | <1% | 1,880 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 453 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $5K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 261 | $5K |
| 73110 | <1% | 108 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 476 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $4K |
| 84100 | <1% | 1,695 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 958 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 56 | $4K |
| 82570 | <1% | 1,319 | $4K | |
| 71250 | <1% | 16 | $4K | |
| 73030 | <1% | 72 | $4K | |
| 80305 | <1% | 315 | $4K | |
| 93225 | <1% | 93 | $4K | |
| 93226 | <1% | 92 | $4K | |
| 86901 | <1% | 1,929 | $4K | |
| 86900 | <1% | 1,943 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 105 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 215 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 23 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 28 | $3K |
| 82105 | <1% | 221 | $3K | |
| 86756 | <1% | 226 | $3K | |
| 87040 | <1% | 395 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 189 | $3K |
| 20553 | <1% | 6,237 | $3K | |
| 99385 | <1% | 175 | $3K | |
| 95024 | <1% | 92 | $2K | |
| 0012A | <1% | 145 | $2K | |
| 84156 | <1% | 1,112 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 20 | $2K |
| 93296 | <1% | 180 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,161 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,666 | $2K |
| 74019 | <1% | 28 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 450 | $2K |
| 76770 | <1% | 40 | $2K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 75 | $2K |
| 82950 | <1% | 360 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 61 | $2K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 47 | $2K |
| 0002A | <1% | 108 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,717 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 41 | $1K |
| 86769 | <1% | 42 | $1K | |
| 73565 | <1% | 733 | $1K | |
| 0001A | <1% | 207 | $1K | |
| 86677 | <1% | 97 | $997.35 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 236 | $991.44 |
| 84146 | <1% | 67 | $912.49 | |
| 76942 | <1% | 16 | $790.51 | |
| 83605 | <1% | 112 | $759.00 | |
| 72100 | <1% | 18 | $737.49 | |
| 76820 | <1% | 32 | $731.75 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 70 | $673.63 |
| 0011A | <1% | 66 | $636.13 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,988 | $562.20 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 50 | $556.52 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $530.40 |
| J3490 | Unclassified drugs | <1% | 2,923 | $503.95 |
| 82728 | <1% | 63 | $492.47 | |
| 85651 | <1% | 174 | $476.07 | |
| 87075 | <1% | 93 | $464.72 | |
| 82077 | <1% | 36 | $446.25 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 728 | $425.97 |
| 87077 | <1% | 85 | $415.49 | |
| 84410 | <1% | 21 | $410.34 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 39 | $406.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 402 | $384.95 |
| 85378 | <1% | 60 | $358.48 | |
| 87186 | <1% | 71 | $340.66 | |
| 84403 | <1% | 19 | $335.54 | |
| 84134 | <1% | 89 | $302.97 | |
| 86140 | <1% | 104 | $298.06 | |
| 82962 | <1% | 98 | $260.70 | |
| 82627 | <1% | 15 | $244.53 | |
| 83001 | <1% | 18 | $222.97 | |
| 83002 | <1% | 18 | $222.25 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 413 | $198.77 |
| 82785 | <1% | 22 | $197.52 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 94 | $174.38 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 42 | $152.87 |
| Q3014 | Telehealth originating site facility fee | <1% | 425 | $149.59 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 22 | $146.37 |
| 83540 | <1% | 29 | $129.40 | |
| 84402 | <1% | 27 | $101.89 | |
| 87205 | <1% | 78 | $94.60 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 97 | $85.47 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 80 | $77.80 |
| 82043 | <1% | 12 | $69.36 | |
| 91301 | <1% | 209 | $53.36 | |
| 83550 | <1% | 12 | $43.70 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $35.82 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,541 | $31.11 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 16 | $26.51 |
| 91300 | <1% | 216 | $15.92 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 40 | $8.58 |
| 90837 | Psychotherapy session, about an hour | 0% | 57 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 24 | $0.00 |
| 00000 | 0% | 1,047 | $0.00 | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 15 | $0.00 |
| 02024 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSOILEAU, KIRK (CEO)
| Provider | Location | Paid |
|---|---|---|
| Natchitoches Parish Hospital Service District | Campti, LA | $1.41M |
| Natchitoches Parish Hospital Service District | Natchitoches, LA | $5K |
| Natchitoches Parish Hospital Service District | Natchitoches, LA | $3.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.